Processa Enters Agreement to Develop HT-100 as Possible Fibrotic Disease Treatment
Processa Pharmaceuticals announced it has entered into a global licensing agreement with Akashi Therapeutics to possibly develop and market HT-100, Akashi’s candidate to treat diseases associated with tissue fibrosis (scarring) and inflammation, including scleroderma. HT-100 is an experimental, oral small molecule reported to have strong anti-inflammatory…